Immuron Receives FDA Approval for Travelan IND Application

MELBOURNE, Australia, Dec. 23, 2022.Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials